-transparent.png){kind=logo}
hCG is a putative thyroid stimulator. The present studies were undertaken to examine its interaction and that of its desialylated variant asialo-hCG with recombinant human TSH (hTSH) receptor (hTSHr). To this end, we transfected a human thyroid carcinoma cell line (HTC) lacking endogenous TSHr with the full-length cDNA of the hTSHr. Unlike the wild type, the transfected cells, termed HTC-TSHr cells, were able to bind bovine TSH (bTSH) with high affinity and increase cAMP production in response to bTSH stimulation. Of the hCG forms, intact hCG displayed a weak activity to inhibit [125I] bTSH binding to HTC-TSHr cells, with 100 mg/L (2.6 x 10(-6) mol/L) producing maximally a 20% inhibition, whereas asialo-hCG achieved half-maximum binding inhibition at a concentration of 8 mg/L (2.3 x 10(-7) mol/L). The inhibitory constant (Ki) of asialo-hCG for recombinant hTSHr was calculated from saturation experiments in the presence of variable doses of bTSH and a fixed concentration of asialo-hCG to be approximately 8 x 10(-8) mol/L. The interaction of asialo-hCG with TSHr was further assessed by studies of the direct binding of the radioactively labeled hormone to both HTC and HTC-TSHr cells. [125I]Asialo-hCG binding to HTC-TSHr cells was 4.7%, compared to 1.5% in the wild-type cells lacking TSHr and was displaceable by bTSH (0.1-100 IU/L), indicating specific binding of the tracer to TSHr. Functionally, hCG (up to 100 mg/L; 2.6 x 10(-6) mol/L) proved unable to evoke any significant cAMP response over basal values in HTC-TSHr cells, as did asialo-hCG. Asialo-hCG, but not hCG, inhibited bTSH-stimulated adenylate cyclase activity in the cells in a dose-dependent manner. In conclusion, the present data show that intact hCG binds only weakly to HTC-TSHr cells and produces no significant cAMP stimulation, which is at variance with data obtained in FRTL-5 and Chinese hamster ovary-TSHr cells, but in good accord with previous findings in human thyroid membranes. Asialo-hCG, on the other hand, strongly binds to recombinant TSHr and inhibits the cAMP response to bTSH in HTC-TSHr cells, indicating that the desialylated hCG variant directly interacts with the receptor and truly is an antagonist of the hTSHr.
R Hoermann, and
M Broecker, and
M Grossmann, and
K Mann, and
M Derwahl
June 1992,
The Journal of clinical endocrinology and metabolism,
R Hoermann, and
M Broecker, and
M Grossmann, and
K Mann, and
M Derwahl
February 1980,
The Journal of clinical endocrinology and metabolism,
R Hoermann, and
M Broecker, and
M Grossmann, and
K Mann, and
M Derwahl
January 1967,
The Medical letter on drugs and therapeutics,
R Hoermann, and
M Broecker, and
M Grossmann, and
K Mann, and
M Derwahl
March 1969,
Therapie der Gegenwart,
R Hoermann, and
M Broecker, and
M Grossmann, and
K Mann, and
M Derwahl
April 1972,
Endocrinology,
R Hoermann, and
M Broecker, and
M Grossmann, and
K Mann, and
M Derwahl
July 1990,
Molecular and cellular endocrinology,
R Hoermann, and
M Broecker, and
M Grossmann, and
K Mann, and
M Derwahl
March 1995,
Nihon rinsho. Japanese journal of clinical medicine,
R Hoermann, and
M Broecker, and
M Grossmann, and
K Mann, and
M Derwahl
December 1999,
Nihon rinsho. Japanese journal of clinical medicine,
R Hoermann, and
M Broecker, and
M Grossmann, and
K Mann, and
M Derwahl
July 2010,
Nihon rinsho. Japanese journal of clinical medicine,
R Hoermann, and
M Broecker, and
M Grossmann, and
K Mann, and
M Derwahl
August 2005,
Nihon rinsho. Japanese journal of clinical medicine,
